Samsung Biologics Co.,Ltd. (KRX:207940)

Samsung Biologics Revenue

Samsung Biologics had revenue of 1.32T KRW in the quarter ending June 30, 2026, with 30.24% growth. This brings the company's revenue in the last twelve months to 5.12T, up 50.31% year-over-year. In the year 2025, Samsung Biologics had annual revenue of 4.56T with 30.31% growth.

• Revenue (ttm): 5.12T
• Revenue Growth: +50.31%
• P/S Ratio: 12.62
• Revenue / Employee: 961.55M
• Employees: 5,326
• Market Cap: 64.64T

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	4.56T	1.06T	30.31%
Dec 31, 2024	3.50T	-197.44B	-5.34%
Dec 31, 2023	3.69T	693.29B	23.10%
Dec 31, 2022	3.00T	1.43T	91.41%
Dec 31, 2021	1.57T	403.23B	34.62%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 18, 2026

Data Sources Report a data error